JP2023022124A - インターフェロンの送達のためのマイクロニードルシステム - Google Patents
インターフェロンの送達のためのマイクロニードルシステム Download PDFInfo
- Publication number
- JP2023022124A JP2023022124A JP2022184543A JP2022184543A JP2023022124A JP 2023022124 A JP2023022124 A JP 2023022124A JP 2022184543 A JP2022184543 A JP 2022184543A JP 2022184543 A JP2022184543 A JP 2022184543A JP 2023022124 A JP2023022124 A JP 2023022124A
- Authority
- JP
- Japan
- Prior art keywords
- interferon
- microneedle array
- polyvinylpyrrolidone
- formulation
- microneedle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000014150 Interferons Human genes 0.000 title claims abstract description 41
- 108010050904 Interferons Proteins 0.000 title claims abstract description 41
- 229940079322 interferon Drugs 0.000 title claims abstract description 35
- 239000000203 mixture Substances 0.000 claims abstract description 43
- 238000009472 formulation Methods 0.000 claims abstract description 41
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims abstract description 26
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims abstract description 26
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims abstract description 25
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 14
- 201000006417 multiple sclerosis Diseases 0.000 claims description 11
- 235000011187 glycerol Nutrition 0.000 claims description 6
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 4
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 4
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 4
- 229920000136 polysorbate Polymers 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 3
- 150000002016 disaccharides Chemical class 0.000 claims description 3
- 229950008882 polysorbate Drugs 0.000 claims description 3
- 239000002736 nonionic surfactant Substances 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 229940127557 pharmaceutical product Drugs 0.000 claims description 2
- 150000005846 sugar alcohols Polymers 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims 1
- 239000000470 constituent Substances 0.000 abstract description 6
- 108090000467 Interferon-beta Proteins 0.000 description 26
- 102000003996 Interferon-beta Human genes 0.000 description 26
- 239000004480 active ingredient Substances 0.000 description 16
- 238000002493 microarray Methods 0.000 description 16
- 210000003491 skin Anatomy 0.000 description 15
- 230000000694 effects Effects 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 238000003860 storage Methods 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 108010005716 Interferon beta-1a Proteins 0.000 description 6
- 230000000840 anti-viral effect Effects 0.000 description 6
- 229940047124 interferons Drugs 0.000 description 6
- 238000003491 array Methods 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 241000710188 Encephalomyocarditis virus Species 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 210000000434 stratum corneum Anatomy 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000037368 penetrate the skin Effects 0.000 description 3
- 230000000149 penetrating effect Effects 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000004873 anchoring Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 229940003504 avonex Drugs 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 229960004461 interferon beta-1a Drugs 0.000 description 2
- 244000309715 mini pig Species 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 229940038850 rebif Drugs 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000037317 transdermal delivery Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 206010022004 Influenza like illness Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229910010293 ceramic material Inorganic materials 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 210000000736 corneocyte Anatomy 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- -1 ethoxylated sorbitan fatty acid esters Chemical class 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 108700027921 interferon tau Proteins 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007391 self-medication Methods 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0023—Drug applicators using microneedles
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Anesthesiology (AREA)
- Medical Informatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Media Introduction/Drainage Providing Device (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
a)本発明によるマイクロニードルシステムを皮膚に固定する工程;および
b)ポリビニルピロリドンを含む完全に可溶性の配合物を含むマイクロニードルアレイを皮膚に穿通させる工程であり、ポリビニルピロリドンが配合物の主要な構成要素である工程
を含む、方法に関する。
は、任意の形状および性質のものであり、インターフェロンを皮膚に投与するために、マイクロニードルアレイが、第1のポジションから第2のポジションに提供されることを主に達成する。さらにアプリケーターは、プッシュボタンまたは他のトリガー機構を含むことができる。
発性硬化症研究の専門家は、皮膚の上層における免疫コンピテントな標的細胞の近傍に活性成分を直接的に放出することによって高い効力が達成できるとの意見である。より重要なことに、専門家によると、より低い活性成分濃度により、匹敵する処置の成功を達成し、望ましくない副作用が頻繁に生じることを大幅に最小化できる可能性がある。ベータインターフェロン注射(皮下(SC)または筋肉内(IM))後、患者の全血流は非常に短い時間内に高濃度のサイトカインで通常満たされる。このことは活性成分の皮内適用で回避される、というのも、活性成分が、間質液およびリンパ系にのみ初期に到達し、対応する効力(これがCNSに作用する免疫カスケードの開始である)がここでトリガーされるからである。
Claims (11)
- インターフェロンの皮内送達における使用のためのポリビニルピロリドンを含む完全に可溶性の配合物を含むマイクロニードルアレイであって、ポリビニルピロリドンは該配合物の主要な構成要素である、前記マイクロニードルアレイ。
- インターフェロン含有量はマイクロニードルアレイ当たり0.1μgから200μgである、請求項1に記載の使用のためのポリビニルピロリドンを含む完全に可溶性の配合物を含むマイクロニードルアレイ。
- 前記配合物は二糖、非イオン性界面活性剤、ポリアルコール、および特にグリセロール(グリセリン)を含む、請求項1または2に記載の使用のためのポリビニルピロリドンを含む完全に可溶性の配合物を含むマイクロニードルアレイ。
- 前記配合物はトレハロースおよび/またはポリソルベートおよび/またはグリセリンを含む、請求項1~3のいずれか1項に記載の使用のためのポリビニルピロリドンを含む完全に可溶性の配合物を含むマイクロニードルアレイ。
- 請求項1~4のいずれか1項に記載のポリビニルピロリドンを含む完全に可溶性の配合物を含むマイクロニードルアレイを含む製品、特に医薬製品であって、インターフェロンの皮内送達における使用のための、特に多発性硬化症の処置のためのまたはインターフェロン療法のための、前記製品。
- 請求項1~5のいずれか1項に記載のインターフェロンの皮内送達における使用のためのマイクロニードルアレイまたは製品であって、配合物は最大95重量%のポリビニルピロリドンならびにさらにアジュバントおよび添加剤を含む、前記マイクロニードルアレイまたは製品。
- 請求項1~6のいずれか1項に記載のインターフェロンの皮内送達における使用のためのマイクロニードルアレイまたは製品であって、配合物は最大95重量%のポリビニルピロリドンおよび0.1重量%から45重量%のトレハロースを含む、前記マイクロニードルアレイまたは製品。
- 請求項1~7のいずれか1項に記載のインターフェロンの皮内送達における使用のためのマイクロニードルアレイまたは製品であって、配合物は最大95重量%のポリビニルピロリドンおよび0.001重量%から10重量%のポリソルベートを含む、前記マイクロニードルアレイまたは製品。
- 請求項1~8のいずれか1項に記載のインターフェロンの皮内送達における使用のためのマイクロニードルアレイまたは製品であって、配合物は最大95重量%のポリビニルピロリドンおよび0.1重量%から10重量%のグリセリンを含む、前記マイクロニードルアレイまたは製品。
- 請求項1~9のいずれか1項に記載のマイクロニードルアレイ、およびアプリケーターを含む、マイクロニードルシステム。
- 請求項10に記載のマイクロニードルアレイ、およびアプリケーターを含む、マイクロニードルシステムであって、該アプリケーターはトリガーデバイスを含む、前記マイクロニードルシステム。
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102018109460.4 | 2018-04-19 | ||
DE102018109460 | 2018-04-19 | ||
DE102018114930.1 | 2018-06-21 | ||
DE102018114930 | 2018-06-21 | ||
JP2020557205A JP2021522171A (ja) | 2018-04-19 | 2019-04-23 | インターフェロンの送達のためのマイクロニードルシステム |
PCT/EP2019/060396 WO2019202170A1 (de) | 2018-04-19 | 2019-04-23 | Mikronadelsystem zur applikation von interferon |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020557205A Division JP2021522171A (ja) | 2018-04-19 | 2019-04-23 | インターフェロンの送達のためのマイクロニードルシステム |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2023022124A true JP2023022124A (ja) | 2023-02-14 |
Family
ID=66597522
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020557205A Pending JP2021522171A (ja) | 2018-04-19 | 2019-04-23 | インターフェロンの送達のためのマイクロニードルシステム |
JP2022184543A Pending JP2023022124A (ja) | 2018-04-19 | 2022-11-18 | インターフェロンの送達のためのマイクロニードルシステム |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020557205A Pending JP2021522171A (ja) | 2018-04-19 | 2019-04-23 | インターフェロンの送達のためのマイクロニードルシステム |
Country Status (12)
Country | Link |
---|---|
US (1) | US20230330010A1 (ja) |
EP (1) | EP3781127B1 (ja) |
JP (2) | JP2021522171A (ja) |
KR (2) | KR102658659B1 (ja) |
CN (1) | CN112055582B (ja) |
AU (1) | AU2019254726B2 (ja) |
BR (1) | BR112020020159A2 (ja) |
CA (1) | CA3097617C (ja) |
ES (1) | ES2905483T3 (ja) |
MX (1) | MX2020011004A (ja) |
PL (1) | PL3781127T3 (ja) |
WO (1) | WO2019202170A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102017112573A1 (de) * | 2017-06-07 | 2018-12-13 | Lts Lohmann Therapie-Systeme Ag | Mikronadelsystem zur Applikation von Glukagon-ähnlichen-Peptid Analoga |
DE102021118997A1 (de) | 2021-07-22 | 2023-01-26 | Lts Lohmann Therapie-Systeme Ag. | Mikronadelarray mit Antiseptika |
CN113599501B (zh) * | 2021-08-25 | 2022-11-29 | 北京三元基因药业股份有限公司 | 一种稳定的干扰素微针制剂及其制备方法与应用 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1294215C (en) * | 1986-10-27 | 1992-01-14 | Ze'ev Shaked | Pharmaceutical compositions of recombinant beta-interferon and formulation processes |
US6887462B2 (en) * | 2001-04-09 | 2005-05-03 | Chiron Corporation | HSA-free formulations of interferon-beta |
DE10353629A1 (de) | 2003-11-17 | 2005-06-16 | Lts Lohmann Therapie-Systeme Ag | Vorrichtung zur transdermalen Verabreichung von Wirkstoffen |
EP1940459B1 (en) | 2005-09-06 | 2014-04-09 | Theraject, Inc. | Solid solution perforator containing drug particle and/or drug-adsorbed particles |
PT2097068E (pt) * | 2006-11-24 | 2013-10-23 | Cadila Healthcare Ltd | Formulações de conjugados de peg-interferão alfa |
US20130041330A1 (en) * | 2010-02-24 | 2013-02-14 | Hisamitsu Pharmaceutical Co., Inc. | Micro-needle device and preparation method |
CN104069484A (zh) * | 2014-03-28 | 2014-10-01 | 上海交通大学 | 干扰素微针及其制备方法和应用 |
KR101950693B1 (ko) * | 2014-07-24 | 2019-02-21 | 주식회사 엘지생활건강 | 레티놀 또는 레티놀 유도체를 함유하는 마이크로니들 |
JP2018039761A (ja) * | 2016-09-08 | 2018-03-15 | コスメディ製薬株式会社 | 双針型マイクロニードル |
-
2019
- 2019-04-23 AU AU2019254726A patent/AU2019254726B2/en active Active
- 2019-04-23 KR KR1020237021323A patent/KR102658659B1/ko active IP Right Grant
- 2019-04-23 WO PCT/EP2019/060396 patent/WO2019202170A1/de active Application Filing
- 2019-04-23 CA CA3097617A patent/CA3097617C/en active Active
- 2019-04-23 EP EP19725032.7A patent/EP3781127B1/de active Active
- 2019-04-23 JP JP2020557205A patent/JP2021522171A/ja active Pending
- 2019-04-23 KR KR1020207032903A patent/KR102555433B1/ko active IP Right Grant
- 2019-04-23 BR BR112020020159-6A patent/BR112020020159A2/pt not_active Application Discontinuation
- 2019-04-23 ES ES19725032T patent/ES2905483T3/es active Active
- 2019-04-23 PL PL19725032T patent/PL3781127T3/pl unknown
- 2019-04-23 CN CN201980028986.4A patent/CN112055582B/zh active Active
- 2019-04-23 MX MX2020011004A patent/MX2020011004A/es unknown
-
2022
- 2022-11-18 JP JP2022184543A patent/JP2023022124A/ja active Pending
-
2023
- 2023-06-15 US US18/210,144 patent/US20230330010A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
KR102658659B1 (ko) | 2024-04-17 |
CA3097617C (en) | 2023-01-24 |
EP3781127A1 (de) | 2021-02-24 |
KR20210003164A (ko) | 2021-01-11 |
WO2019202170A1 (de) | 2019-10-24 |
US20230330010A1 (en) | 2023-10-19 |
EP3781127B1 (de) | 2022-01-12 |
CN112055582B (zh) | 2023-09-29 |
CA3097617A1 (en) | 2019-10-24 |
BR112020020159A2 (pt) | 2021-01-05 |
KR102555433B1 (ko) | 2023-07-13 |
CN112055582A (zh) | 2020-12-08 |
AU2019254726B2 (en) | 2022-10-06 |
KR20230098709A (ko) | 2023-07-04 |
AU2019254726A1 (en) | 2020-11-12 |
JP2021522171A (ja) | 2021-08-30 |
PL3781127T3 (pl) | 2022-05-02 |
ES2905483T3 (es) | 2022-04-08 |
MX2020011004A (es) | 2020-11-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2023022124A (ja) | インターフェロンの送達のためのマイクロニードルシステム | |
KR101634836B1 (ko) | 마이크로 니들 디바이스 | |
US10973757B2 (en) | Biodegardable microneedle device | |
CN111212675B (zh) | 用于将微针阵列施用于皮肤的施用装置 | |
EP2129366B1 (en) | Solid pharmaceutical and vaccine dose | |
EP2566501A2 (en) | Method and device for transdermal delivery of parathyroid hormone using a microprojection array | |
US11135170B2 (en) | Solid formulation | |
EP2957298A1 (en) | Microneedle coating composition and microneedle device | |
Moreno et al. | Skin vaccination using microneedles coated with a plasmid DNA cocktail encoding nucleosomal histones of Leishmania spp. | |
US20210346664A1 (en) | Sandwiched biodegradable microneedle | |
KR20150005137A (ko) | 나노 크기의 구멍을 가진 마이크로니들 및 이의 제조 방법 | |
Duong et al. | Highly prolonged release of the cancer vaccine and immunomodulator via a two-layer biodegradable microneedle for prophylactic treatment of metastatic cancer | |
US11690799B2 (en) | Microneedle system for applying interferon | |
JP2023169415A (ja) | 肝炎ワクチンの適用のためのマイクロニードルシステム | |
RU2821323C2 (ru) | Микроигольчатая система для доставки интерферона | |
RU2814278C2 (ru) | Микроигольная система для введения вакцины от гепатита | |
KR102484179B1 (ko) | 펩타이드 계열 유효 성분을 포함하는 마이크로 니들 및 이를 제조하기 위한 제형 조성물 | |
Dillon et al. | Development of Novel Transdermal Drug Delivery Technologies for Therapeutic Peptides | |
AU2014253541B2 (en) | Solid pharmaceutical and vaccine dose | |
KR20170032809A (ko) | B형 간염 치료를 위한 용해성 미세바늘 패치 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221216 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20221216 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231107 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240207 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20240423 |